Clinical Trials Browser

Terminated × Breast Neoplasms × Epirubicin × Clear all

NCT01779050 2022-11-01

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Phase 2 Terminated

7 enrolled 8 charts

Breast Neoplasms

NCT03894007 2021-09-23

PREDIXIIHER2

Phase 2 Terminated

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms

NCT00625898 2020-09-10

BETH

Phase 3 Terminated

Breast Neoplasms

NCT00176488 2017-03-23

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Phase 2 Terminated

31 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00912444 2016-11-22

NATT

Phase 3 Terminated

Breast Neoplasms

NCT01985841 2015-10-08

Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT00756470 2014-11-17

Phase II Neoadjuvant in Inflammatory Breast Cancer

Phase 2 Terminated

15 enrolled 10 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01301040 2013-08-30

Early Cardiac Toxicity of Adjuvant CT in Elderly BC.

Phase 2 Terminated

Breast Neoplasms, Cardiotoxicity

NCT00431795 2013-02-13

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT00193024 2011-05-03

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT00162812 2008-07-18

TOP

Phase 2 Terminated

Breast Neoplasms, Inflammatory Breast Neoplasms